Storia in 3 fonti

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease. | Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease.

Raccontata da

fiercepharma.com

statnews.com

biopharmadive.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo1 g fa

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

originale

statnews.com2 g fa

FDA approves Roivant therapy for rare autoimmune disease

The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.

Leggi questa versione → originale

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Confronto fonti

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

FDA approves Roivant therapy for rare autoimmune disease

Timeline cronologica

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground

FDA green lights Priovant drug for rare skin disease

FDA approves Roivant therapy for rare autoimmune disease

FDA green lights Priovant drug for rare skin disease

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease